Reproductive Rights – Mifepristone Access
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2025-01-23 — SAVE Moms and Babies Act of 2025: cross-connection with save-moms-and-babies-act-reproductive-rights: SAVE Moms and Babies Act would codify tighter FDA restrictions on mifepristone (in-person dispensing, prescriber certification, ≤70-day labeling), directly constraining the access pathway tracked on the mifepristone page. (novelty: 3)
- 2026-06-24 — To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.: HR9421 (119th Congress) introduced to prohibit REMS-certified providers from prescribing mifepristone without an in-person patient visit and without holding a medical license in the patient’s state of residence, which would effectively end telehealth-based medication abortion across state lines. (novelty: 2)
Open questions
Related
Contributing findings
To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
24-jun-2026
novelty 2
per-area 2
introduces